Association of tet methylcytosine dioxygenase 2 and 5-hydroxymethylcytosine in endometrioid adenocarcinoma and its clinical significance

Author:

Kuang Lei,Zhang Jingbo,Li Yanyu,Wang Qing,Liu Jianwei,Zhang Bei

Abstract

Abstract Background Aberrant DNA methylation is a vital molecular alteration commonly detected in type I endometrial cancers (EC), and tet methylcytosine dioxygenase 2 (TET2) and 5-hydroxymethylcytosine (5hmC) play significant roles in DNA demethylation. However, little is known about the function and correlation of TET2 and 5hmC co-expressed in EC. This study intended to investigate the clinical significance of TET2 and 5hmC in EC. Methods The levels of TET2 and 5hmC were detected in 326 endometrial tissues by immumohistochemistry, and the correlation of their level was detected by Pearson analysis. The association between the levels of TET2 and 5hmC and clinicopathologic characteristics was analyzed. Prognostic value of TET2 and 5hmC was explored by Kaplan–Meier analysis. The Cox proportional hazard regression model was used for univariate and multivariate analyses. Results Based on the analysis results, TET2 protein level was positively correlated with 5hmC level in EC tissues (r = 0.801, P < 0.001). TET2+5hmC+ (high TET2 and high 5hmC) association was significantly associated with well differentiation, myometrial invasion, negative lymph node metastasis, and tumor stage in EC. Association of TET2 and 5hmC was confirmed as a prognostic factor (HR = 2.843, 95%CI = 1.226–3.605, P = 0.007) for EC patients, and EC patients with TET25hmC level had poor overall survival. Conclusions In summary, the association of TET2 and 5hmC was downregulated in EC tissues, and may be a potential poor prognostic indicator for EC patients. Combined detection of TET2 and 5hmC may be valuable for the diagnosis and prognosis of EC.

Funder

Xuzhou introduced clinical medical expert team project

Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy

the Jiangsu Science and Technology planning project

Publisher

Springer Science and Business Media LLC

Reference37 articles.

1. Ha Thout L, Wang Y, Wang Q, Vergalasova I, Lee LJ. A multi-institutional analysis of adjuvant chemotherapy and radiation sequence in women with Stage IIIC endometrial cancer. Int J Radiat Oncol Biol Phys. 2021;110:1423–31.

2. Joannie LT, Jacques F, Freddie B, Ahmedin J. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst. 2018;110:4.

3. Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncology. 2012;13:e353–61.

4. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer Lacent. 2016;387:1094–108.

5. JIn W, Wang L, Liu Y, Liu A. Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer. Chin J Obstet Gynecol. 2018;053:823–30.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3